Journal article icon

Journal article

In vitro evidence to support amphotericin B and flucytosine combination therapy for talaromycosis

Abstract:
Background: Talaromyces marneffei causes talaromycosis, a life-threatening fungal disease with limited treatment options. The standard treatment of amphotericin B (AmB) induction followed by itraconazole consolidation still results in 15% to 30% mortality. This study aimed to investigate the potential of AmB and flucytosine (5FC) combination therapy to enhance antifungal activity. Methods: The in vitro antifungal activity of AmB and 5FC alone and in combination against 60 T. marneffei clinical isolates was evaluated using a validated colorimetric antifungal susceptibility assay and the checkerboard method. The minimum inhibitory concentration (MIC) was defined as the lowest drug concentration inhibiting ≥ 95% fungal growth (MIC95) for both AmB and 5FC. The combination effect between AmB and 5FC against T. marneffei was determined using fractional inhibitory concentration index. Combination effects were further tested using a time-kill assay. Results: The MIC95 was 0.25 – 2 μg/mL (geometric mean [GM] 0.68 μg/mL) for AmB, and 0.03 – 0.5 μg/mL (GM 0.28 μg/mL) for 5FC. Full synergy was observed in 4 isolates (7%), and indifference was observed in the remaining 56 isolates (93%). The time-kill experiments revealed a concentration-dependent fungicidal activity of AmB, and concentration-independent fungistatic effect of 5FC. Synergy between AmB and 5FC was confirmed, showing greater than 2-log10 reduction in colony forming units when used in combination. No antagonism was observed. Conclusions: Our study demonstrated in vitro evidence of synergistic activity between AmB and 5FC against T. marneffei, providing the evidence to support in vivo and clinical trial testing of AmB and 5FC combination therapy, and dosing reduction strategies of 5FC.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1371/journal.pntd.0013884

Authors

More by this author
Role:
Author
ORCID:
0009-0007-8729-6121


More from this funder
Funder identifier:
https://ror.org/01d35cw23
More from this funder
Funder identifier:
https://ror.org/01cwqze88
More from this funder
Funder identifier:
https://ror.org/025kprq56
More from this funder
Funder identifier:
https://ror.org/05ag50972


Publisher:
Public Library of Science
Journal:
PLoS Neglected Tropical Diseases More from this journal
Volume:
19
Issue:
12
Pages:
e0013884
Article number:
e0013884
Publication date:
2025-12-31
Acceptance date:
2025-12-19
DOI:
EISSN:
1935-2735
ISSN:
1935-2727


Language:
English
Keywords:
Pubs id:
2355878
UUID:
uuid_307b993a-c772-4bb7-95d8-d97be7582b0a
Local pid:
pubs:2355878
Source identifiers:
3645587
Deposit date:
2026-01-08
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP